Confirm candidacy
Confirm whether you are a candidate for cytoreductive surgery with HIPEC.
Specialized Unit
Peritoneal Carcinomatosis of Gastric Origin
At Quenet-Torrent Institute, we treat peritoneal carcinomatosis of gastric origin with cytoreductive surgery and HIPEC in carefully selected patients, always within a multidisciplinary context.
CONTACT SPECIALISTNeed to speak with a specialist?
Complete the form and schedule your appointment to speak directly with the surgeon
-
EXTENSIVE EXPERIENCE +20,000 surgeries performed
-
LATEST TECHNOLOGY in surgical strategy
-
PERSONALIZED CARE First contact within 24/48h
Schedule your consultation with a specialist
What is gastric peritoneal carcinomatosis?
Gastric peritoneal carcinomatosis is the spread of gastric cancer cells to the peritoneum. It is one of the most common forms of gastric cancer progression and has traditionally been considered a terminal condition.
However, advances in multimodal treatment have shown that in carefully selected patients, the combination of cytoreductive surgery and HIPEC can significantly improve survival and even offer cure potential in limited cases.
Strict patient selection is key. Results depend on the extension of peritoneal disease (PCI), response to systemic treatment, and technical achievability of complete cytoreduction.
Why request a second opinion for gastric carcinomatosis?
Requesting a second opinion can reveal treatment options not initially considered.
Evaluate response
Evaluate response to systemic chemotherapy and surgical options.
Compare approaches
Compare the palliative approach with potentially curative options in specialized centers.
Clinical trials
Consider participation in clinical trials with innovative treatments including prophylactic HIPEC.
A specialized evaluation can change the prognosis in selected patients.
How do we treat gastric carcinomatosis?
Treatment in selected cases combines systemic chemotherapy with locoregional surgery in a multimodal approach.
Neoadjuvant chemotherapy
Systemic treatment to evaluate tumor biology and select patients with chemosensitive disease.
Cytoreductive surgery
Complete removal of all visible peritoneal disease when technically and oncologically feasible.
HIPEC
Hyperthermic intraperitoneal chemotherapy to treat microscopic residual disease after cytoreduction.
Prophylactic HIPEC
In selected cases at high risk of peritoneal recurrence at the time of initial gastrectomy.
Patient selection is strict and based on multiple clinical, radiological, and pathological factors.
Our Technology
Technology for treating gastric carcinomatosis
Precise technology helps in patient selection and surgical execution.
Staging laparoscopy
Direct PCI evaluation and resectability assessment before committing to open surgery.
PET-CT
Detection of extra-abdominal disease that would contraindicate surgery.
Automated HIPEC equipment
Precise thermal and flow control during intraperitoneal perfusion.
Multidisciplinary tumor board
All cases discussed in a specialized committee with surgeons, oncologists, and radiologists.
WHY CHOOSE US?
Experience in complex gastric cases
Quenet-Torrent Institute offers a comprehensive approach, with teams specialized in advanced peritoneal disease.
Experience in Complex Cases
We specialize in treating advanced and metastatic cancer, using innovative techniques that other teams do not offer.
Comprehensive Multidisciplinary Approach
We form a team around you with surgeons, oncologists, radiologists, nutritionists, and psychologists, all working together for your cure.
Research and Innovation
We stay up to date with the latest scientific advances, allowing us to apply innovative treatments with better results.
State-of-the-Art Technology
We have facilities equipped with the most current medical technology, allowing us to perform high-precision procedures with less impact on the body.
Personalized and Close Care
We care about each patient as a person. We listen, support, and guide every step of the way.
Our Team
Gastric carcinomatosis specialists
Every physician at Quenet-Torrent Institute is a recognized expert in their field, committed to each patient's well-being.
Dr. François Quenet
Oncological Surgeon
View doctor"Internationally renowned surgeon, expert in gastrointestinal and hepatobiliary tumors. Recognized for his precision in highly difficult surgeries."
Dr. Juan José Torrent
Oncological Surgeon
View doctor"Specialist in gynecological tumors and peritoneal carcinomatosis. A reference in complex and personalized oncological surgery."
Frequently asked questions about gastric carcinomatosis
Answers to the most common questions about diagnosis, treatment, and prognosis.
Can gastric carcinomatosis be cured?
In very selected cases with limited disease and good response to chemotherapy, long-term survival is possible. Strict selection criteria apply Outcomes depend on histology, PCI score, and completeness of cytoreduction.
Who is a candidate for surgery?
Patients with limited peritoneal disease, good general condition, and favorable response to systemic treatment after multidisciplinary tumor board evaluation.
What is prophylactic HIPEC?
Application of HIPEC at the time of gastrectomy in patients at high risk of peritoneal recurrence — an approach being evaluated in clinical trials Our experienced team adapts the treatment approach to each clinical situation.
How long is the recovery?
Hospitalization is usually 10-14 days and complete recovery 2-3 months, though this may vary depending on the extent of surgery performed El equipo valora cada caso.
Is a second opinion necessary?
Always recommended to confirm whether you are a candidate for surgical treatment — eligibility criteria are strict and require specialized evaluation.
Where can I receive this treatment safely?
In specialized centers with experience in peritoneal surface malignancies, like Quenet-Torrent Institute Chemotherapy complements surgery to optimise overall oncological control.
Easy Contact
Need to speak with a specialist?
Complete the form and schedule your appointment to speak directly with the surgeon.